Purpose: Cladribine (2-chlorodeoxyadenosine, 2-CdA) has been reported to be effective in the treatment of low-grade lymphomas. The objective of this multicenter study was to evaluate the activity of cladribine in mantle-cell lymphomas as first-line therapy or in first relapse using an intermittent two-hour infusion of cladribine.
Introduction

Patients and methods
It is proposed that mantle-cell lymphoma (MCL), previously described as centrocytic lymphoma in the Kiel Classification, be defined as a new entity by the Revised European-American Classification of Lymphoid Neoplasms (R.E.A.L.) [1] . MCL patients are resistant to current therapeutic strategies and have the shortest median survival of all those with lymphoma entities with a median survival of three to four years, irrespective of the initial treatment [2] . New agents are therefore needed to improve on the prospects of current treatment approaches. Cladribine (2-chlorodeoxyadenosine, 2-CdA) is a newer purine analogue resistant to deamination by adenosine deaminase [3, 4] , which has shown high activity -response rates from 42% to 88% -in the treatment of low-grade lymphomas [5] [6] [7] [8] . In most studies cladribine was administered as continuous infusion for seven days. The objective of the present study was to evaluate the efficacy and toxicity of cladribine as an intermittent twohour infusion over five days in patients with MCL as first-line therapy or therapy of first relapse.
This report is part of a prospective phase II trial started in 1994 in 15 participating centers evaluating the activity of cladribine in different lymphoma entities [7] . It was approved by the Ethics Committee of the University Hospital of Frankfurt. All patients gave their written informed consent. The study was performed in accord with good clinical practice.
Eligibility criteria
Patients were eligible for entry into the study if they had a histologically-confirmed diagnosis of MCL according to the R.E.A.L. Classification. All lymph node and bone marrow biopsies were reviewed by a single German referral center for haematopathology. Patients were required to have received no prior chemotherapy or to have had a first relapse after pretreatment with one regimen not containing purine analogues and to have a performance status of ^ 2, and to be between 18 and 75 years of age. Patients were staged by using the Ann Arbor classification.
Treatment
Cladribine (supplied by Janssen-Cilag, Neuss, Germany) was administered in doses of 5 mg/m 2 per day over five consecutive days by twohour intravenous infusion. The treatment was repeated every four to five weeks for a maximum of six cycles, and was discontinued in instances of complete remission (CR), disease progression, severe side effects, or persistant decrease of CD4-positive lymphocytes below [14] . 100/uI. No prophylactic antibiotic treatment including pneumocystis carinii pneumonia prophylaxis was given.
Criteria for response and toxicity
Response and treatment-related toxicity were assessed according to WHO criteria. CR was defined by the disappearance of all measurable disease and a return to normal blood counts as well as by bonemarrow lymphocyte percentage less than 30% in aspiration and biopsy material and no evidence of abnormal lymphoid infiltration. Partial response (PR) required a > 50% reduction of disease manifestations and a > 50% improvement of all abnormal blood counts. Progression was denned as a > 25% increase in measurable disease. Blood counts were determined weekly. Time to progression was assessed through clinical and radiological examinations at three-month intervals until relapse. Bone marrow biopsy was repeated every six months as part of the response evaluation procedure.
Statistical methods
Progression-free survival (PFS) was the period from the beginning of remission to disease progression. Overall survival was calculated from the first day of treatment to death. Survival rates were estimated by the Kaplan-Meier method.
Results
Twelve patients with MCL entered the study between April 1994 and April 1997. All of them had stage IV disease and bone marrow involvement. The characteristics of the patients are listed in Table 1 .
Seven patients achieved remission with three CR and four PR and an overall remission rate of 58% (95% CI: 28%-85%). Four relapsed after 7, 10,11, and 19 months, respectively, and three patients still have ongoing remissions lasting 8, 19, and 21 months. The median time to progression was 19 months (range 7-21+ months). There was no statistical difference in duration of PFS between CRs and PRs and between previously untreated and pretreated patients.
Up to now five patients have died, four of them of progressive disease refractory to cladribine as well as to subsequent salvage therapies, and the fifth patient of intestinal perforation following surgery for diverticulitis, after being in CR for eight months. The median duration of survival has not yet been reached; the actuarial survival rate at 36 months is 59%.
Toxicity
Nonhaematological toxicity was generally mild, mainly restricted to WHO grades 1 and 2. Nausea, vomiting and alopecia were not observed. There were no treatmentrelated deaths. Granulocytopenia was the most common side effect, with grade 3 occurring in 10 (21%) of 47 evaluable cycles. No thrombocytopenia grade 3 or 4 was observed. One patient had a reactivated tuberculosis, which was treated successfully. No other severe or opportunistic infections were observed. CD4-positive lymphocytes with a median of 700/ul before treatment decreased to 360/^1 after two, 180/ul after four, and 169/ul after six cycles. To evaluate the recovery of CD4-positive lymphocytes, the CD4-positive counts were measured 12 and 24 months after cessation of therapy, showing sustained depression with median values of 195/ul and 324/ul, respectively. No infections have been seen during the time period from cessation of therapy after reaching a response or in the time interval when a salvage therapy had to be initiated for a recurrence.
Discussion
Cladribine activity has been reported in relapsing or resistant low-grade lymphomas, with achievement of response rates of 42% to 66% [5, 6] . Recently published studies showed response rates of 75% to 88% in previously untreated low-grade lymphoma patients using cladribine as continuous infusion for seven days [6, 8] .
Our study represents one of the first reports establishing an activity of cladribine in patients with MCL achieving an overall response rate of 58% treated with an intermittent two-hour-infusion regimen. We observed ongoing remissions of 8, 19, and 21 months. Patients refractory to cladribine did not respond to salvage therapies, including CHOP, Dexa-BEAM and high-dose chemotherapy with stem cell rescue, demonstrating the very limited therapeutic options in this disease. In our study the remission rates of MCL patients treated with cladribine were inferior to those of patients with follicular or lymphoplasmacytoid lymphomas [7] . Overall results in MCL remain poor, corresponding to the generally known unfavorable prognosis of this entity [9] . The response rate in our study is in accordance with a recent trial reporting a response rate of 63% in eight patients with MCL [10] . In contrast to this study the rate of infectious complications as well as the degree of thrombocytopenia as a possible severe side effect of cladribine therapy was lower in our experience. However, due to the low number of patients in both studies, firm conclusions cannot be drawn from these data.
The combination of cladribine with other agents, such as anthracyclines or mitoxantrone, which have been demonstrated to have fair activity in MCL [11] , may improve treatment results. Saven et al. demonstrated that cladribine can be combined with mitoxantrone in low-grade lymphomas [12] . Preclinical evaluation of cladribine-induced apoptosis in lymphoma cells in vitro in our laboratory showed supraadditive effects of cladribine with anthracyclines or mitoxantrone [13] . In an ongoing phase II study we evaluate the activity of cladribine in combination with mitoxantrone in patients with MCL.
In conclusion, our study indicates that MCL responds to cladribine with some long-lasting remissions but a response rate lower than in other entities such as follicular or lymphoplasmacytoid lymphomas. Efforts should be made to combine cladribine with other agents in the treatment of MCL.
